Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

RDEA119 and Sorafenib Combination Dose Escalation Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00785226
First received: November 4, 2008
Last updated: October 14, 2016
Last verified: October 2016